Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions

This study investigates the pharmacokinetics of yohimbine in women and men aged 18 to 40 years to explore sex-specific differences in CYP2D6-dependent drug metabolism. Participants will be classified by their CYP2D6 genotype into extensive metabolizers (EM) and poor metabolizers (PM), forming four distinct study arms: Arm 1) Women, Poor Metabolizers (PM) n=13 Arm 2) Women, Extensive Metabolizers (EM) n=5 Arm 3) Men, Poor Metabolizers (PM) n=13 Arm 4) Men, Extensive Metabolizers (EM) n=5 Each study arm will receive a single oral dose of 50 µg yohimbine (2 x 1 tablets, 25 µg per tablet) and 25 mg of ¹³C₃-caffeine co-administered as a drinking solution. The purpose of this study is: 1. To characterize the pharmacokinetics of yohimbine following a single oral dose in women and men across different CYP2D6 phenotypes. 2. To evaluate yohimbine's suitability as a reliable probe for assessing CYP2D6 activity. 3. To investigate potential interactions between CYP2D6 and CYP1A2, as well as interindividual variability in CYP1A2-dependent caffeine metabolism.

NCT Number	NCT06939608
Lead Sponsor	University Medicine Greifswald
Conditions	Pharmacokinetic Study in Healthy Volunteers
Enrollment	36 participants
Start Date	2025-04-28
Primary Completion	2025-10-10 (estimated)
Study Completion	2025-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-01-21